<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>The medical therapy of heart failure (HF) has been traditionally based on inhibiting the main pathophysiologic mechanisms: the adrenergic and renin-angiotensin-aldosterone systems. Introducing the therapeutical triad of beta-blockers, angiotensin converting enzyme inhibitors and mineralocorticoid receptor antagonists in the treatment of HF patients almost 40 years ago marked an important step since they were not only addressing the symptoms of HF, but also the prognosis and life- expectancy of these patients. Although many discoveries have been made in the past years, no other therapeutic class was able to increase survival among HF patients, until recently, when th SA e benefits of modulating the natriuretic peptide system were brought to the attention of the scientific community. Increasing the levels of natriuretic peptides with Sacubitril/ Valsartan (SV) led to several benefits for the reduced ejection fraction HF population, including less long and short term complications, increased survival and a reduced symptom burden. As this article is being written, it is estimated that more than 2.8 million patients are being treated with SV<sup>(1)</sup>. Therefore, SV is an important and validated therapy for HF patients and internists should be aware of its indications, benefits and management in clinical practice.</p>
</abstract>

The medical therapy of heart failure (HF) has been traditionally based on inhibiting the main pathophysiologic mechanisms: the adrenergic and renin-angiotensin-aldosterone systems. Introducing the therapeutical triad of beta-blockers, angiotensin converting enzyme inhibitors and mineralocorticoid receptor antagonists in the treatment of HF patients almost 40 years ago marked an important step since they were not only addressing the symptoms of HF, but also the prognosis and life- expectancy of these patients. Although many discoveries have been made in the past years, no other therapeutic class was able to increase survival among HF patients, until recently, when th SA e benefits of modulating the natriuretic peptide system were brought to the attention of the scientific community. Increasing the levels of natriuretic peptides with Sacubitril/ Valsartan (SV) led to several benefits for the reduced ejection fraction HF population, including less long and short term complications, increased survival and a reduced symptom burden. As this article is being written, it is estimated that more than 2.8 million patients are being treated with SV(1). Therefore, SV is an important and validated therapy for HF patients and internists should be aware of its indications, benefits and management in clinical practice.

About Sacubitril/Valsartan: A Clinically-Oriented Primer for Internists

“Dr. Carol Davila” Central University Emergency Military Hospital

Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"About Sacubitril/Valsartan: A Clinically-Oriented Primer for Internists"}

The medical therapy of heart failure (HF) has been traditionally based on inhibiting the main pathophysiologic mechanisms: the adrenergic and...

About Sacubitril/Valsartan: A Clinically-Oriented Primer for Internists

Pubblicato online: 13 set 2021

Pagine: 39 - 45

DOI: https://doi.org/10.2478/inmed-2021-0173

Parole chiave
sacubitril, valsartan, natriuretic peptide, heart failure, reduced ejection fraction, neprilysin

© 2021 Mihnea Casian et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

About Sacubitril/Valsartan: A Clinically-Oriented Primer for Internists

Pubblicato online: 13 set 2021

Pagine: 39 - 45

DOI: https://doi.org/10.2478/inmed-2021-0173

Parole chiavesacubitril, valsartan, natriuretic peptide, heart failure, reduced ejection fraction, neprilysin

© 2021 Mihnea Casian et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
sacubitril, valsartan, natriuretic peptide, heart failure, reduced ejection fraction, neprilysin